If you live with obsessive-compulsive disorder (OCD), you probably know how exhausting it can be to have your mind return to the same thought again and again. You know the thought may be irrational. You may desperately want to stop engaging with it. And yet your brain keeps pulling you back. This is one of the reasons new research into psilocybin for OCD is so interesting.
In March 2026, psychiatrist Dr. Francisco Moreno and researchers at the University of Arizona published results from a randomized clinical trial investigating repeated doses of psilocybin in people with OCD. The study was tiny—only 15 participants—so we need to be careful about what we conclude. But the results were intriguing. After repeated psilocybin sessions, researchers observed significant reductions in OCD symptoms, with some participants eventually meeting criteria for remission. So what exactly happened? And could psilocybin actually help interrupt the seemingly endless thought loops of OCD?
OCD is much more than being organized, particular, or wanting things to be clean. At its core, OCD involves obsessions and compulsions. Obsessions are unwanted intrusive thoughts, images, sensations, fears, or urges. Compulsions are behaviors or mental rituals used to reduce the distress created by those obsessions. The problem is that performing the compulsion can reinforce the cycle. A thought appears. Anxiety rises. You perform a behavior or mental ritual to feel safe. You experience temporary relief. Then the thought returns. The brain essentially learns:
“When this thought appears, I need to do something about it.” And the loop becomes stronger. For someone living inside that cycle, the possibility of temporarily disrupting it can be extremely meaningful.
Interestingly, Dr. Francisco Moreno’s investigation into psychedelics and OCD didn’t begin with a laboratory theory. It began with something a patient told him. Moreno treated a person with severe, treatment-resistant OCD who reported that when he used psychedelics such as LSD or psilocybin mushrooms, his obsessions and compulsions temporarily disappeared. That observation raised an important question: What if psychedelics could temporarily change the processes keeping obsessive-compulsive patterns in place? Moreno and colleagues eventually conducted an early clinical study published in 2006 investigating psilocybin in nine people with OCD. Twenty years later, his team has returned with a more rigorous randomized clinical trial.
The new study, published in the Journal of Psychopharmacology, included 15 adults with OCD. Participants were randomly assigned to receive four weekly sessions of:
There were five participants in each group. After this initial four-week randomized phase, participants entered a second phase in which they could receive four additional high-dose psilocybin sessions. This meant some participants received up to eight psychedelic sessions separated by approximately one week. OCD symptoms were measured using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), one of the standard clinical tools used to measure OCD severity.
This is where the study becomes particularly interesting. During the randomized portion of the trial, psilocybin produced reductions in obsessive-compulsive symptoms. The high-dose group showed significant improvement, while the placebo group did not. When researchers combined the low- and high-dose psilocybin groups, OCD symptoms across the first four weeks were significantly lower than in the placebo group. By the end of the eight-week treatment period, after all participants had received at least four high doses:
73.3% were classified as responders. A responder was defined as someone experiencing at least a 35% reduction in Y-BOCS scores.
Even more striking: 40% met the study’s criteria for remission.
The improvements became smaller over time, but meaningful benefits were still observed during the six-month follow-up. Researchers also found an association between cumulative psilocybin exposure and symptom improvement: participants receiving greater cumulative exposure tended to experience larger reductions in OCD symptoms. That does not mean that more psilocybin automatically equals better outcomes. With only 15 participants, that finding needs to be replicated in much larger studies. But it raises an important question for future psychedelic research: perhaps OCD treatment may involve a therapeutic process across multiple sessions rather than expecting one psychedelic experience to permanently change the condition.
We don’t know yet. But there are interesting reasons scientists are investigating this possibility. Psilocybin is converted in the body into psilocin, which strongly interacts with serotonin 5-HT2A receptors. These receptors are involved in complex processes related to perception, cognition, mood, and brain-network activity. One hypothesis in psychedelic neuroscience is that psychedelics may temporarily make certain patterns of brain activity less rigid. Think about walking through a field every day using exactly the same path. Eventually, you create a deep trail. Your brain begins following that trail automatically because it has traveled there thousands of times. OCD can sometimes feel like that psychologically.
Thought → fear → compulsion → relief → thought again.
Psilocybin may temporarily change the landscape enough that the brain isn’t forced down exactly the same familiar path. That doesn’t mean the old pathway magically disappears. It may simply create an opportunity for something different to happen. And that distinction matters.
One of the most interesting questions isn’t whether psilocybin eliminates intrusive thoughts. It’s whether the relationship to those thoughts can change. People with OCD often don’t suffer simply because an unusual thought appears. Humans have strange thoughts all the time. The suffering often comes from the importance the brain assigns to the thought and the urgent feeling that something must be done about it.
What if a thought could simply be a thought?
Not a warning. Not a prophecy. Not evidence about who you are. Not something requiring an immediate response. Just neurological activity passing through consciousness. That possibility is particularly interesting when thinking about psilocybin and OCD. But we still need research showing exactly why symptoms improve and which psychological or neurological mechanisms are responsible.
The 2026 study also provides unusual information about repeated psilocybin dosing. Some participants received as many as eight high-dose sessions approximately one week apart. Within this small, carefully controlled clinical study, researchers reported that psilocybin was generally well tolerated.
There were:
That is encouraging. But it should not be interpreted as evidence that taking psilocybin every week is safe for everyone. These participants were screened, monitored and treated within a clinical research environment. Psychedelics can produce intense psychological experiences and may carry particular risks for people with certain psychiatric conditions or vulnerabilities. A clinical trial is very different from self-treatment.
This part is extremely important. Fifteen people is a very small sample. The researchers themselves conclude that larger clinical trials are needed to establish effectiveness and determine appropriate treatment protocols.
We also don’t yet know:
For OCD, evidence-based treatments such as Exposure and Response Prevention (ERP) and medications including serotonin reuptake inhibitors remain established clinical approaches. Psilocybin should currently be understood as an experimental treatment being investigated, not a replacement for established OCD care.
Moreno’s team isn’t stopping here. Researchers are now investigating whole psilocybin-containing mushrooms while examining changes in the brain using tools including neuroimaging and EEG. This next stage is especially interesting because symptom scores tell us whether something changed. Brain imaging may eventually help us understand how it changed. Researchers can begin asking deeper questions: What happens to brain networks associated with rigid thinking? Does communication between different brain regions change? Can those neurological changes predict who improves? And perhaps most importantly:
Can those changes last?
Longer follow-up periods will help researchers understand whether psychedelic-assisted approaches could eventually become a meaningful therapeutic option for some people living with OCD.
The science is promising. But it is still early. The 2026 Moreno study gives us something more substantial than anecdotes: a randomized clinical trial showing that repeated psilocybin administration was associated with meaningful reductions in OCD symptoms in a small group of participants. At the end of treatment, approximately 73% met response criteria and 40% met remission criteria. Those numbers deserve attention. They do not deserve exaggeration. For people who know what it feels like to wake up and immediately find themselves trapped inside the same intrusive thought, the possibility that the brain’s patterns may not be as permanent as they feel is powerful. Perhaps the most interesting question psychedelic research is asking isn’t:
“Can mushrooms make OCD disappear?”
It is:
“Can we create a window in which a deeply reinforced mental pattern becomes flexible enough to change?”
Twenty years after Moreno’s first psilocybin-OCD study, we are finally beginning to get better answers.
And this research is far from finished.
Moreno FA, Allen KE, Wiegand CB, Dunne R, Prickett JI, Bayze B, Allen JJB. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. Journal of Psychopharmacology. 2026;40(5):837–849. DOI: 10.1177/02698811261424214. PMID: 41825921.
Educational disclaimer: This article is for educational purposes and does not constitute medical advice or encourage self-treatment with psilocybin. Psilocybin remains regulated or illegal in many jurisdictions, and psychedelic experiences can carry psychological and physical risks. People considering treatment for OCD should speak with a qualified healthcare professional.
